Alumis reports new Phase 3 data for envudeucitinib in psoriasis
Alumis said new Phase 3 data show envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality-of-life measures, building on ONWARD3 Week 48 results.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Alumis announces new Phase 3 data
Alumis said it has new Phase 3 data and outlined plans to submit an NDA for envudeucitinib in the fourth quarter of 2026.
Alumis reports phase 3 psoriasis data for envudeucitinib
Alumis said envudeucitinib met phase 3 measures across scalp disease, itch and quality of life in its ONWARD program. The company also said it remains on track to submit an NDA in the fourth quarter of 2026.